Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab Plus Chemotherapy and Nivolumab in Advanced Gastric and GEJ Cancer (FORTITUDE-102)
NCT05111626Phase 3Terminated
- Sponsor
- Amgen
- Start
- Mar 2022
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of bemarituzumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events up to 4.5 years and 1 more. Started Mar 2022; status: terminated.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05111626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111626.